Rilotumumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Rilotumumab (AMG 102) 是一种 anti-HGF (抗肝细胞生长因子) 的单克隆抗体，抑制 HGF/MET 驱动的信号传导。Rilotumumab 具有抗肿瘤活性，可用于去势抵抗性前列腺癌 (CRPC) 和实体瘤的研究。

Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.

Rilotumumab (10 μg/mL; overnight) shows the decrease of MET phosphorylation at Y1234 and Y1235, and an increase in total MET.Western Blot Analysis Cell Line:U87MG.vIII cells Concentration:10 μg/mL Incubation Time:Overnight Result:Showed MET phosphorylation at tyrosine residue 1234 (Y1234) and Y1235 ~50% lower in U87MG.vIII cells than in untreated cells.Showed an increase in total MET compared with untreated cells.

Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo.Animal Model:6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells Dosage:1.5 mg/kg Administration: Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days Result:Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001).

——

Angiogenesis

c-Met/HGFR

c-Met/HGFR

——

——

872514-65-3

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years